Risankizumab in CD: Outcomes Remain Stable up to 3 Years
STOCKHOLM, Sweden — Long-term data on risankizumab (Skyrizi) in moderate to severe Crohn's disease (CD) show that clinical remission and ...
Read moreDetails
Tag: Risankizumab
The Earth News is an independent English-language daily published Website from all around the World News
